Results 161 to 170 of about 6,457 (202)

DYRK1A inhibition restores pancreatic functions and improves glucose metabolism in a preclinical model of type 2 diabetes. [PDF]

Mol Metab
Bertrand R, Tolu S, Picot D, Tourrel-Cuzin C, Ouahab A, Dairou J, Deau E, Lindberg MF, Meijer L, Movassat J, Uzan B.   +10 more
europepmc   +1 more source

Computer-aided discovery of triazolothiadiazoles as DYRK1A-targeted neuroprotective agents. [PDF]

RSC Med Chem
Si X, Wang Y, Qiu N, Qian C, Yang B, Jin H, Wang H, Zhang X, Xia J.   +8 more
europepmc   +1 more source

Correction to "AI-Driven <i>De Novo</i> Design and Development of Nontoxic DYRK1A Inhibitors". [PDF]

J Med Chem
García EG, Varas Pardo P, González-Naranjo P, Ulzurrun E, Marcos-Ayuso G, Pérez C, Páez JA, Insua DR, Santana SR, Campillo NE.   +9 more
europepmc   +1 more source

Probing Allosteric Kinase Modulators as Next Game-Changers in Fighting Neurodegeneration. [PDF]

J Med Chem
Roggiolani E, Rosini M, Minarini A, Basagni F.   +3 more
europepmc   +1 more source

Discovery of Dietary Plant Flavonols as Novel Potent Inhibitors Targeting DYRK1A Kinase. [PDF]

Biomolecules
Jin J, Zhou Q, Guo B, Jia Z.
europepmc   +1 more source

Ripply3 overdosage induces mid-face shortening through Tbx1 downregulation in Down syndrome models. [PDF]

PLoS Genet
Ahumada Saavedra JT, Chevalier C, Bloch Zupan A, Herault Y.   +3 more
europepmc   +1 more source

Common tissue-specific expressions and regulatory factors of c-KIT isoforms with and without GNNK and GNSK sequences across five mammals. [PDF]

PLoS One
Goto R, Sakamoto N, Awazu A.
europepmc   +1 more source

The enigmatic role of tumor dormancy cells in gynecologic cancers. [PDF]

Front Immunol
Fu A, Ma Z, Zou K, Wu F, Zou X.
europepmc   +1 more source